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Introduction
Heart failure is often the consequence
of cardiac myocyte loss after insult,
such as myocardial infarction. Patients
hospitalized with an index episode of
heart failurehave a prognosis aslow as
patients with common malignancies
(Stewart et al, 2001). With the excep-
tion of heart transplantation and
implantation of mechanical ventricular
assist devices, current therapies do
not address the central problem of
decreased pumping capacity owing to
a depleted pool of cardiac myocytes.
Thus, there has been enormous interest in the prospect of
cardiac regeneration rather than slowing the inexorable decline
of heart function.
Until recently, the prospect of cardiac regeneration was
largely a subject of science ﬁction. The longstanding paradigm
held that the mammalian heart is a terminally differentiated
organ, incapable of replenishing any myocyte attrition. During
the past decade, however, studies revealed not only that
mammalian cardiac myocytes retain some capacity for division
(Beltrami et al, 2001), but also identiﬁed endogenous cardiac
progenitor cells in the heart (Beltrami et al, 2003) or bone
marrow (Orlic et al, 2001). These cells retain some potential for
differentiation into the cellular components of the heart,
including endothelial cells, smooth muscle cells and cardiac
myocytes.
If progenitor cells residing in the adult are capable of
producing new heart cells, the therapeutic delivery of such
progenitors might facilitate the generation of de novo functional
myocardium. In this context, cell-based therapies for the heart
havebeen rapidlytranslated into theclinictotreatheartdisease,
but randomized clinical trials with bone marrow progenitors
have shown at best modest improvements in ventricular
function (Martin-Rendon et al, 2008). In short, the promise of
complete cardiac regeneration has not yet been realized.
In light of mixed results from clinical trials, it is worth
revisiting both the foundations of cardiac regeneration and
highlight recent advances that may portend future directions in
the ﬁeld. We will ﬁrst deﬁne the problem, that is elucidating
the scope of endogenous mammalian regeneration and, by
extension, the scale of the regenerative deﬁcit. We will then
summarize current regenerative approaches, including both
cell-based therapies and pharmacoregenerative strategies. In
this context, we will summarize the many challenges that stand
in the way of cardiac regeneration, both endogenous repair
processes and exogenous regenerative therapies.
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The death of cardiac myocytes diminishes the heart’s pump function and is a major
cause of heart failure, one of the dominant causes of death worldwide. Other than
transplantation, there are no therapies that directly address the loss of cardiac
myocytes,which explainsthecurrent excitementincardiac regeneration.Theﬁeldis
evolving in two important directions. First, although endogenous mammalian
cardiac regeneration clearly seems to decline rapidly after birth, it may still persist
in adulthood. The careful elucidation of the cellular and molecular mechanisms of
endogenous heart regeneration may therefore provide an opportunity for develop-
ing therapeutic interventions that amplify this process. Second, recent break-
throughs have enabled reprogramming of cells that were apparently terminally
differentiated, either by dedifferentiation into pluripotent stem cells or by trans-
differentiation into cardiac myocytes. These achievements challenge our con-
ceptions of what is possible in terms of heart regeneration. In this review, we
discuss the current status of research on cardiac regeneration, with a focus on the
challenges that hold back therapeutic development.
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The regenerative deﬁcit of the mammalian heart is obvious
when compared with organisms such as zebraﬁsh and newts,
which demonstrate a remarkable survival capacity after
removal of up to 20% of the heart by transection of the
ventricular apex (Oberpriller & Oberpriller, 1974; Poss et al,
2002). Pre-existing cardiac myocytes adjacent to the site appear
to undergo a process of dedifferentiation, characterized by
dissolution of sarcomeric structures. This is followed by
incorporation of deoxyribonucleic acid (DNA) synthesis
markers (e.g. nucleotide analogues) consistent with prolifera-
tion (Jopling et al, 2010; Kikuchi et al, 2010; Laube et al, 2006).
Ultimately, newly generated cardiac myocytes are functionally
integrated with the preexisting myocardium. The heart is left
with little residual evidence of the injury, thus providing a
natural example of complete myocardial regeneration.
Evidence for heart regeneration in mammals
During embryonic development and the early post-natal period,
mice also demonstrate a remarkable regenerative capacity.
Embryos heterozygous for a cardiac myocyte-speciﬁc null
mutation in the x-linked holocytochrome c synthase (Hccs)
gene demonstrate cardiac myocyte replacement during foetal
development (Drenckhahn et al, 2008): when one of two
X-chromosomes is randomly inactivated in each female somatic
cell, approximately 50% of the cardiac myocytes are rendered
Hccs-null and hence dysfunctional. Proliferative functional
Hccs-expressing cardiac myocytes compensate for dysfunctional
Hccs-null myocytes, such that, at birth, 90% of the heart is
derived from myocytes containing one functional Hccs allele.
Similar plasticity in post-natal mice is conﬁned to the ﬁrst week
after birth; apical excision results in myocyte proliferation and
structural restoration similar to regeneration in zebraﬁsh
and newts (Porrello et al, 2011). Afterwards, however, injured
myocardium is largely replaced by ﬁbrosis and scarring.
Distinguishing whether the adult mammalian heart is incapable
of cardiac myocyte replacement or whether it retains a low-level
capacityforrepairisthereforefundamentally importantbecause
evenlow-levelmyocyteturnoverraisesthespecterofamplifying
that response for therapeutic ends. Thus, it is worth reviewing
boththeevidencesupporting theevolving viewofamoreplastic
mammalian heart, while closely considering potential artefacts
that may affect the interpretation of these results.
The ﬁrst arguments against the paradigm of the terminally
differentiated quiescent cardiac myocyte date back decades; the
increasing force of these arguments reﬂects the emergence
of new data made possible by methodological innovations. Early
evidence supporting cardiac myocyte plasticity relied on
mathematical modelling of the myocyte population based
on cytometric indices. For example, the measured average
volume increase of cardiac myocytes was calculated to fall
short of the increase predicted by the observed volumetric
changes in the whole heart (Astorri et al, 1971). These data
andsimilaranalysesbased onDNAcontent asserted thatchanges
in heart volume could not be explained by hypertrophy alone,
and that cardiac myocyte hyperplasia (increase in cell number)
contributed to changes in heart mass. However, these studies
were not widely accepted because their conclusions relied on a
number of assumptions about myocyte size and DNA content.
Modern microscopic analyses to detect cell cycle markers
such as Ki67 or the incorporation of nucleotide analogues (e.g.
iododeoxyuridine or
3H-thymidine) into newly synthesized
DNA further support the notion that the mammalian heart may
generate new myocytes both during normal homeostasis and
after injury. Multiple studies have demonstrated that murine or
Review
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Glossary
Cardiac myocytes
Heart muscle cells.
Fibrosis
Development of excessive fibrous connective tissue in an organ.
Gastrulation
Early phase of embryonic development during which the germ layers form.
Heart failure
Condition in which theheart is not abletopump enough bloodintotherest
of the body. Also called congestive heart failure.
Ki67
Marker protein for cell proliferation.
Mesodermal
Pertainingtothemesoderm.Mesodermisoneofthethreegerm layers,which
forms skeletal muscle, the skeleton, the dermis of skin, connective tissue, the
urogenital system, the heart, blood (lymph cells), the kidney and the spleen.
Nucleotide analogues
Nucleotides, which contain chemical modifications and are incorporated
into the DNA during synthesis and cell proliferation. They can thus be
easily detected.
Polyploid
Cells or organisms that contain one or more extra sets of chromo-
somes.
Progenitor—ancestor
A cell that can differentiate into a specific cell type.
Sarcomeric
Pertaining to thesarcomere. Sarcomere is oneofthesegmentsintowhich a
striated muscle is divided.
Stromal cells
Cells of the connective tissue of any organ.
Teratomas
Congenital, encapsulated tumours, which contain one or more germ
layers.
Transcription factors
Proteins, which are involved in regulation of gene expression after binding
to a specific DNA sequence.
Transdifferentiation
The conversion of one differentiated cell to another cell type.
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described rates of this phenomenon differ by more than one
order of magnitude (Beltrami et al, 2001; Kajstura et al, 2010a,b;
Soonpaa & Field, 1997).
Recent dating experiments, made possible by nuclear arms
testing in the middle of the 20th century, provide the most
convincing evidence for post-natal human cardiac myocyte
turnover. Since the Partial Test Ban Treaty of 1963, the marked
spike in atmospheric
14C levels has dissipated as the biosphere
absorbed the carbon. Thus, the period of nuclear testing serves
as a historical DNA labelling pulse, and the period after the test
ban treaty serves as a chase. The genomic DNA of cells
generated during either the pulse or the chase reﬂect the earth’s
atmospheric
14C concentration at that point in time, which
allows investigators to date the age of cardiac myocytes by
measuring the concentration of
14C in their nuclei (Bergmann et
al, 2009). It showed that the adult heart contains some cardiac
myocytes generated during the human life-span; their model
predictedan approximateturnover rateof1% peryear atage 25,
declining to a rate of 0.45% by the age of 75.
Confounding factors in the quantitation of cardiac
myocyte turnover
The data generated by these diverse methodologies support the
notion that the mammalian heart has conserved some capacity
for cardiac myocyte turnover though there is lingering con-
troversy about the scope of the mammalian heart’s endogenous
regenerativecapacity.Studiesrelyingontheidentiﬁcationmitotic
cardiac myocytes (Kajstura et al, 1998), immuno-detection of cell
cycle markers such as Ki67 (Beltrami et al, 2001) or of IdU
incorporationintonewlysynthesizedDNA(Kajsturaetal,2010b)
suggestthatnearly30%oftheheartcanbereplacedwithin1year
during normal homeostasis, a rate that increases 50-fold after
injury. These remarkably high rates imply that the entire heart is
replaced approximately every 3 years during normal home-
ostasis,andthatallcardiacmyocyteslosttoaninfarctioncouldbe
replaced within 3 weeks. In contrast, data from nuclear fallout
studies (Bergmann et al, 2009) and quantitative studies of DNA
synthesis using autoradiographic measurement of
3H-thymidine
incorporation (Soonpaa & Field, 1997) indicate turnover rates of
1% or less per year.
The actual scale of the endogenous regenerative response
has important implications for rational therapeutic design. If the
turnover rate is relatively low, therapeutic interventions should
focus on replacing lost or dysfunctional myocytes. If the
mammalian heart indeed has a robust intrinsic capacity for
myocyterepletion,thetherapeuticfocusshouldshifttopromoting
theassemblyofendogenouslygeneratedmyocytesintofunctional
myocardium. Thus, in the context of discrepant evidence about
the true scale of endogenous mammalian regeneration, it is
worth reviewing potential sources of bias inherent to all existent
methodologies that are used to study cell fate.
The difﬁculty of measuring cardiac myocyte turnover in the
heart is largely a result of the slow rate of myocyte turnover
relative to adjacent stromal cells (Bergmann et al, 2009). Within
a timeframe that is practical to directly measure the generation
of cardiac myocytes, the number of newborn cells (numerator)
ismuchsmallerthanthetotalnumberofcells(denominator).As
a result, small errors may magnify projections of absolute yearly
or lifetime myocyte turnover. Another source of error is the
occasional mis-identiﬁcation of cellular components, which is an
inevitable consequence of analyzing a three-dimensional organ
with two-dimensional tissue sections, particularly when relying
on light microscopy which has limited ﬁdelity of resolving
cellular borders in complex tissues like the heart (Laﬂamme &
Murry, 2005). The problem is further exacerbated by the
autoﬂuorescenceofmyocardium,whichcomplicatesanymethod
that relies on the detection of a ﬂuorescent signal, including the
detection of nucleotide analogues, Ki67 or ﬂuorescent labels as
used in genetic lineage-mapping experiments.
Such potential confounders could also affect the
14C dating
method, because it requires the isolation of cardiac myocyte
nuclei by digestion and ﬂow cytometric sorting. Any impurities
in the isolated nuclear preparation could introduce bias to the
analysis; preferential isolation of senescent myocytes could
result in an underestimate of myocyte turnover, whereas an
impure nuclear isolate that includes non-myocyte nuclei might
result in an overestimate.
The heart also presents a unique challenge compared to other
organs owing to the propensity of cardiac myocytes to
synthesize DNA during S-phase without completing either
mitosis and/or cytokinesis (Fig 1). During early post-natal
development, for example, the majority of rodent cardiac
myocytes (Li et al, 1996) and an estimated 25–57% of human
cardiac myocytes (Olivetti et al, 1996; Schmid & Pﬁtzer, 1985)
becomebinucleated.Byadulthood,mostcardiacmyocytenuclei
have also become polyploid with at least one (4n: tetraploid)
or two (8n: octoploid) additional rounds of chromosomal
replication (Bergmann et al, 2010). Although some studies
demonstratedthatthepolyploidyrateinthecardiacmyocytepool
is not affected by ageing or injury (Olivetti et al, 1996), others
suggested that the ploidy state is more dynamic. The ploidy state
of cardiac myocytes may increase with myocardial hypertrophy
or injury (Adler & Friedburg, 1986), which could be mistaken for
myocyte division. Conversely,heartsthathavebeen unloaded by
implantation of a ventricular assist device may have a lower
percentage of polyploid myocytes, because more 2n cardiac
myocytes are being generated (Wohlschlaeger et al, 2010). These
aspects of cardiac myocyte biology inevitably represent potential
confounders that must be considered in any quantiﬁcation of
cardiacmyocyteformation.Aswithanycontroversialhypothesis,
achieving consensus regarding adult mammalian cardiac
myocyte turnover will likely require multiple lines of evidence
using multiple different methodologies.
Defining the cellular source of new cardiac
myocytes
The majority of reports suggest some endogenous capacity for
cardiac myocyte renewal, which has generated a broad focus on
ﬁnding the cellular source of newly generated cardiac myocytes.
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been proposed: division of preexisting mature cardiac myocytes
(Kajstura et al, 1998), ampliﬁcation of dedifferentiated cardiac
myocytes (Jopling et al, 2010; Kikuchi et al, 2010) and
differentiation of progenitor cells (Hsieh et al, 2007). Evidence
exists for all three processes in different species and under
different conditions. It may be possible that more than one of
thesemechanismscanoperatewithinagivenspeciesatdifferent
developmental or pathological stages.
Although there are many reports of mature cardiac myocyte
division in adult mammals, the majority of those reports suggest
that it is a rare event. This is not surprising, given the densely
packed and highly organized sarcomeric contractile apparatus.
In fact, cardiac myocyte replication after injury in the neonatal
mouse, newts and zebraﬁsh is preceded by molecular and/or
cytoskeletal evidence of dedifferentiation (Jopling et al, 2010;
Kikuchi et al, 2010; Oberpriller & Oberpriller, 1974; Porrello
et al, 2011). Cardiac myocytes near the site of injury can
reexpress gene markers of immaturity, like the zinc-ﬁnger
transcription factor GATA binding protein-4 (GATA4), together
with disassembly of sarcomeric structures that is evident
by electron microscopy. This population of dedifferentiated
cardiac myocytes expresses markers of DNA synthesis during
a proliferative phase before redifferentiating into mature cardiac
myocytes.
Newly generated adult mammalian cardiac myocytes may
arise from an endogenous pool of progenitor cells after injury.
Our laboratory developed a genetic lineage mapping approach
to quantify progenitor-dependent cardiac myocyte turnover
(Fig 2) (Hsieh et al, 2007). In the bitransgenic MerCreMer/ZEG
inducible cardiac myocyte reporter mouse, mature cardiac
myocytes undergo an irreversible genetic switch from
constitutive b-galactosidase expression to green ﬂuorescent
protein (GFP) expression upon tamoxifen pulse. During a
chase period, we evaluated the effect of myocardial injury on
the proportion of GFPþ or b-galþ cardiac myocytes. Pressure
overload or myocardial infarction resulted in a signiﬁcant
reduction in the percentage of GFPþ cardiac myocytes and a
corresponding increase in the percentage of B-galþ cardiac
myocytes, consistent with repletion of the myocyte pool
by B-gal  expressing progenitors. Though this approach
theoretically captures the sum progenitor contribution to
myocyte turnover, it cannot directly identify the molecular
identity or anatomic location of the progenitor pool.
One approach to characterizing the molecular phenotype of
cardiac progenitors is to study cardiac embryologic develop-
ment, guided by the assumption that developmental paradigms
are recapitulated during post-natal repair. When examined
through a developmental lens, an increasingly detailed picture
emerges of the soluble and transcriptional signals that guide the
cardiogenic programme from gastrulation (formation of distinct
germ layers) through the ultimate maturation of cardiac
myocytes (Mercola et al, 2011; Yi et al, 2010). The induction
of mesoderm posterior (MESP)-1 expression by brachyury-
expressing primitive mesodermal cells is a proximal require-
ment for the ultimate production of differentiated heart cells
(Bondue et al, 2008; David et al, 2008; Lindsley et al, 2008). As
the developing embryo grows beyond the germ layer phase, its
developing heart receives cells from distinct anatomic progeni-
tor sources: the 1st and 2nd heart ﬁelds provide the majority of
the myocardium, with some contribution from epicardial
progenitors. Certain ﬁelds may be preferentially marked by
speciﬁc transcription factors; for example, the ﬁrst heart ﬁeld by
T-box transcription factor 5 (Tbx5) (Takeuchi et al, 2003), the
second heart ﬁeld by Lim-homeodomain protein Islet1 (Isl1)
(Cai et al, 2003) and epicardial progenitors by Wilms tumour-1
(WT1) or T-box transcription factor 18 (Tbx18) (Cai et al, 2008;
Zhou et al, 2008). Other cardiogenic factors identiﬁed by
embryonic lineage tracing or analysis of gene silencing include
homeobox protein nkx2.5 (Wu et al, 2006), the myocyte
enhancer factor 2C (Mef2c) (Lin et al, 1997) and GATA4
(Molkentin et al, 1997).
In contrast to the relatively well-deﬁned pre-natal develop-
ment, there is no consensus yet about the molecular identity of
post-natal mammalian cardiac progenitor cells or ‘adult cardiac
stem cells’. A number of laboratories have identiﬁed cell
populations within the post-natal mouse, which fulﬁl some
criteria of cardiac progenitors. The common approach of such
studies has been to enzymatically digest myocardial tissue and
to isolate speciﬁc cell populations based on transcriptional
Review
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25–27%
binucleated
Binucleation
Cardiac
myocyte
Polyploidy
66% > 4n
or more
Mitosis
Cytokinesis
Mitosis
Cytokinesis
Mitosis
Cytokinesis
DNA synthesis
Division
Figure 1. The majority of post-natal human DNA synthesis in the heart
does not lead to new myocyte formation. Cardiac myocytes can complete
S-phase, followed by mitosis and cytokinesis (centre) resulting in myocyte
doubling. Cardiac myocytes can also complete mitosis without cytokinesis
(left), resulting in a binucleated cell. Cardiac myocytes can also undergo
chromosomal replication without completing either mitosis or cytokinesis
(right), resulting in polyploidy nuclei. By the completion of post-natal
development, the majority of human myocyte nuclei contain  4n
chromosomal copies.
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etal, 2005)), speciﬁccell surfacereceptor proﬁle(c-kit (Beltrami
et al, 2003) or sca-1 (Oh et al, 2003)), the physiologic capacity to
actively exclude Hoechst dye (so-called side population cells
(Martin et al, 2004)) or based on the outgrowth of typical
spherical colonies in tissue culture (Messina etal, 2004; Smith et
al, 2007) (Fig 3). In general, the label of ‘cardiac stem cell’
results from the observation of self-propagation and cardiac
myocyte transdifferentiation when exposed to cardiogenic
conditions in vitro or when delivered in vivo after injury.
It seemsunlikely that an organ with such limited regenerative
capacity would harbour so many biologically distinct progeni-
tors (Laﬂamme & Murry, 2011; Mercola et al, 2011). Ultimately,
the ﬁeld will beneﬁt from careful in vivo lineage tracing
studies—without ex vivo culture steps—to study if and how a
given cell type contributes to cardiac myocyte replenishment
during either normal homeostasis or after injury (Fig 2). The
lack of such publications to date owes in part to the lack of
speciﬁcity of many stem cell markers, either because they are
also expressed by non-cardiovascular cells/progenitors or
because they may be part of the stress-induced reactivation
of ‘foetal gene programmes’, a phenomenon that is well
documented in adult cardiac myocytes (Bisping et al, 2006;
Kolodziejczyk et al, 1999; Saadane et al, 1999).
Moving towards a regenerative therapy
The plasticity of the mammalian heart and the identiﬁcation of
cell preparations that demonstrate potency for cardiac differ-
entiation hassparkedefforts todevelopregenerativetherapeutic
strategies. The therapeutic challenge is considerable: a typical
large myocardial infarction that leads to heart failure will kill
around 1 billion cardiac myocytes (Laﬂamme & Murry, 2005),
roughly a quarter of the heart’s myocytes (Fig 4). A possible
therapeutic approach would coax an endogenous stem cell
population or an exogenously delivered cell-based therapy to
replace lost cardiac myocytes in a coordinated fashion with
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Figure 2. Lineage-mapping in the adult heart.Left: Theoretical progenitor lineage-mapping is depicted. Progenitors would be selectively marked by fluorescent
protein expression. After injury, the appearance of fluorescently labelled cardiac myocytes would support the concept that these progenitors were contributing to
new myocyte formation. Right: Differentiated cell (cardiac myocyte) lineage-mapping. Upon treatment of the MerCreMer-ZEG mouse with OH-tamoxifen,
approximately 80% of the cardiac myocytes undergo a permanent switch from b-galactosidase to GFP expression. The dilution of the GFP
þ cardiac myocyte pool
after injury is consistent with repletion by b-gal
þ progenitors.
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potential cell-based therapies, no clear winning strategy has
so far emerged (Segers & Lee, 2008).
Bone marrow derived progenitors
A series of nearly simultaneous landmark studies sparked
excitement about a possible adult cardiogenic progenitor
originating outside of the heart. A post-mortem examination
ofmalehearttransplantpatientswhohadreceivedfemaledonor
hearts found that approximately 10% of a-sarcomeric actin-
positive cardiac myocytes had Y-chromosomes. These cells
obviously came from the male patient and from a circulating
progenitor outside of the heart graft (Quaini et al, 2002). Two
other contemporaneous studies suggested that the source of
circulating progenitors could be the bone marrow. In both cases,
a bone marrow cell population with a higher density of the cell
surface receptor c-kit, showed repopulation of murine cardiac
myocytesafterexperimentalmyocardialinfarction(Jacksonetal,
2001; Orlic et al, 2001). Since these initial reports, a number of
studies failed to demonstrate similar rates of chimerism in
transplanted hearts (Deb et al, 2003; Hocht-Zeisberg et al, 2004;
Laﬂamme et al, 2002; Muller et al, 2002) or potency of bone
marrow stem cells (Balsam et al, 2004; Murry et al, 2004) leading
some to postulate that cardiac myocyte transdifferentiation was
overestimated owing to an artefact (Laﬂamme & Murry, 2005).
Nonetheless, some therapeutic effect was observed even in
studies with no detectable transdifferentiation (Balsam et al,
2004). Cell-based therapy using autologous bone marrow
Review
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Figure 3. Possible recapitulation of developmental paradigms by endogenous post-natal cardiac stem cells. Between mesodermal development and the
emergence of cardiac myocytes, cardiovascular progenitors express a number of markers that have also been detected in the various post-natal cardiac stem cell
(CSC) preparations. Expression as measured by messenger RNA (mRNA) or protein expression is denoted with (þ). Absent expression is denoted by ( ).
Blank¼untested.
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Figure 4. The challenge of regenerating the heart. Both exogenously delivered cell therapies and progenitors in the endogenous niche encounter a similar
hostile environment after myocardial injury, often including inadequate blood supply (ischemia), inflammation and fibrosis/scarring. Regenerative pathways may
be activated by as yet unknown paracrine pathways, responsible for recruiting progenitors from the niche, stimulating proliferation and coaxing differentiation.
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ischemic heart disease. A number of randomized trials, using
bone marrow mononuclear cells have been performed and most
studies demonstrated modest cell therapy-mediated improve-
ments in ventricular function. In the largest study to date, the
reinfusion of enriched progenitor cells and infarct remodeling in
AMI (REPAIR-AMI) study (Schachinger et al, 2006), 204
randomized patients with acute myocardial infarctions received
intracoronary delivery of bone marrow cells or vehicle control.
Follow-up after 1 year demonstrated signiﬁcant improvements
in both cardiac function and in a combined clinical endpoint
consisting of death, recurrent myocardial infarct or any
revascularization procedure. In contrast, analysis of 18-month
follow-updatafromthesimilarlyconductedbonemarrowtransfer
to enhance ST-elevation infarct regeneration (BOOST) study
(Meyer et al, 2006), suggested a waning of early improvements in
ventricular function. However, it is worth noting that although
improvements in ventricular function have been modest, no
pattern of adverse events has emerged from these trials.
Bone marrow-derived mesenchymal stem cells have also
been the subject of clinical translation research. These cells are
generated from bone marrow samples that are serially passaged
and cultured on plastic. Though traditionally deﬁned by their
capacity for trilineage differentiation into osteoblasts, chon-
drocytes and adipocytes, mesenchymal stem cells have also
demonstrated evidence for cardiac myocyte differentiation both
in vitro in some culture conditions and when delivered after
myocardial infarction to mice (Toma et al, 2002). Given their
reported tendency to evade rejection owing to ‘immune
privilege’, these cells have been administered to humans as
an allogeneic treatment after myocardial infarct (Hare et al,
2009). The initial clinical experience is consistent with trials
using bone marrow mononuclear cells: patients experience
modest improvements in ventricular function with subtle
improvements in heart failure symptoms. Overall, the experi-
encewithcell-basedtherapiesinhumansdoesnotsupportwide-
spread adoption at this time given their modest beneﬁts,
insufﬁcient safety data and the anticipated quality control costs
of bringing these therapies to the bedside.
Endogenous cardiac progenitors
Since the initial suggestion that the mammalian heart may
contain an endogenous population of progenitor cells (Beltrami
et al, 2003), there has been an intense discussion about the
therapeutic potential of these cells. There are a number of
theoretical advantages to this approach. Autologous transfer
may be feasible, even if an ex vivo expansion stage would
likely be necessary given the small number of stem cells in
heart biopsy specimens. Furthermore, other than cells isolated
from non-cardiac tissue beds, progenitors derived from the
heart itself are theoretically partially pre-programmed to
differentiate into heart cells. However, some reports actually
question the intrinsic stem-like properties of some of the
endogenous adult progenitor preparations, including the
‘stemness’ of adult cardiac c-kitþ cells (Tallini et al, 2009)
and cardiosphere-derived cells (Andersen et al, 2009), both of
which are being used in clinical trials. It is possible that ongoing
trials with these putative endogenous cardiac progenitors will
demonstrate beneﬁts to cardiac function, but this may not
necessarily indicate differentiation into cardiac myocytes.
Pluripotent stem cells
Embryonic stem (ES) cells represent the prototypical stem cells
with the hallmarks of clonogenicity, self-renewal and pluripo-
tency. The potency of these cells also represents a real safety
concern,giventheirtendencytoformteratomas(Nussbaumetal,
2007), even several years after therapeutic delivery (Amariglio
et al, 2009). One approach to overcoming this prohibitive safety
problemhasbeentogeneratepluripotent-derivedprogenitorsthat
have already committed to a cardiogenic pathway. As a proof-of-
principle example of such a strategy, cells with an expression
proﬁle of Oct4, stage-speciﬁc embryonic antigen 1 (SSEA-1) and
MESP1 demonstrated some regenerative potency when delivered
therapeutically in a primate infarct model, without detectable
teratoma formation (Blin et al, in press). One could envision a
similar strategy using cardiogenic intermediates that express any
of the previously mentioned transcription factors associated with
cardiacprogenitorsorcellsurfacemarkerssuchasthereceptorfor
vascularendothelialgrowth factor (Flk1/KDR) (Yang etal,2008).
Yet, such a strategy should still demonstrate both substantial
preclinical efﬁcacy without tumorigenicity before human
translation. If such criteria are met, ES-derived therapies have
the potential of providing ‘off-the-shelf’ cardiac myocytes to treat
acute myocardial infarctions or chronic heart failure.
A second approach, which may also obviate the risk of
teratomas,istogenerate apurepopulationofES-derivedcardiac
myocytes for therapeutic delivery either as a cell suspension or
after ex vivo tissue engineering. There has already been
enormous progress during the past decade in deﬁning the
factors and transcription signals to differentiate cardiac
myocytes from ES-cells. As discussed in greater detail (Noseda
etal,2011),cardiacmyocytedevelopmentisdictatedbythetime
and dose-dependent exposure to a series of growth factors from
the wingless-type MMTV integration site (Wnt), ﬁbroblast
growth factor (FGF), bone morphogenetic protein (BMP) and
nodal families. Guided by these mechanistic insights, several
laboratories have successfully generated ES-derived prepara-
tions with more than 50% of functional cardiac myocytes
(Laﬂamme et al, 2007; Yang et al, 2008). Because of the inherent
technical challenge of delivering a sufﬁcient number of
differentiated cardiac myocytes—not to mention ensuring their
survival and electromechanical integration—the most realistic
future for such technical advances may be as an unlimited
source of cardiac myocytes for engineering myocardial grafts.
The generation of induced pluripotent stem (iPS) cells may
overcome two important limitations of ES cells: ethical concerns
about harvesting ES cells from embryos and graft rejection by
the patient’s immune system, because iPS cells can be custom-
engineered from a patient’s stromal cells for autologous
transplantation. A recent demonstration of heightened
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ever, suggests that the immune system cannot yet be discounted
in the development of iPS-based therapies (Zhao et al, 2011).
The initial protocols for iPS cell generation involved retro-
viral-mediated expression of four stem-cell genes (Takahashi &
Yamanaka, 2006; Yu et al, 2007). As virally reprogrammed cells
may harbour an associated risk of neoplastic conversion,
alternative reprogramming strategies, such as the use of small
molecules (Shi et al, 2008) or non-viral gene modifying
approaches (Warren et al, 2010) will probably be a necessary
component of any future therapeutic strategies. However, the
most important lesson from these landmark studies may be the
remarkable plasticity of even the most terminally differentiated
cells when exposed to the right combination of signals.
Tissue engineering
With stem cells as a potential unlimited source of cardiac
myocytes, engineering ex vivo myocardial grafts could, in
theory, provide another therapeutic approach. The most
clinically advanced tissue engineering to date involves thin,
simple, relatively avascular tissues, such as tracheas (Macchiar-
ini et al, 2008). Owing to the complexity and physiological
requirements of functional myocardial tissue, an abundant
source of cardiac myocytes alone is not enough to build a
clinically useful graft. Historically, the greatest challenge in
tissue engineering has been an adequate supply of oxygen and
nutrients for metabolically active tissues such as the heart. One
approach has been to engineer thin cardiac sheets, which can
then be stacked for in vivo delivery (Shimizu et al, 2002).
Although these layered sheets demonstrate some degree of
electromechanical coordination and neovascularization in vivo,
it is not clear yet if such an approach can be optimized to yield
full-thickness myocardium with an adequate blood supply. The
addition of non-myocyte cellular components, such as ﬁbro-
blasts and endothelial cells, leads to the formation of primitive
vascular structures within engineered grafts, but the electro-
mechanical properties are not sufﬁcient for normal functionality
(Stevens et al, 2009). Ultimately, success in the engineering
of functional, full-thickness myocardium will likely only
be possible if the problem of vascularization is solved
(Zimmermann et al, 2006).
Circumventing cell-based therapy with
pharmacoregeneration?
It is hard to imagine that a single pharmacologic intervention
could lead to complete cardiac repair, but a number of recent
discoveries lend credence to the underlying concept that
paracrine signals may activate repair mechanisms in the heart.
In general, the development of small molecule or protein-based
therapies raises relatively modest problems with quality control
compared to cell-based therapies. Therefore, pharmacoregen-
erative approaches may be a more practical near-term approach
to promote cardiac repair.
Perhaps the most stunning proof-of-principle approach to
generating new cardiac myocytes from endogenous cells is the
recent transformation of resident cardiac ﬁbroblasts into cardiac
myocytes (Ieda et al, 2010). Similar to protocols for generating
iPS cells, the forced expression in cardiac ﬁbroblasts of three
genes—GATA4, MEF2C and TBX5—resulted in the expression
of the cardiac myocyte-speciﬁc myosin heavy chain 6 (Myh6)
promoter in approximately 20% of the cells and spontaneous
beating in approximately 1% of reprogrammed cells. When
isolated cardiac ﬁbroblasts were infected with viruses carrying
the genes encoding the three reprogramming factors and
reintroduced to the heart within 24h, some transformed directly
into cardiac myocytes. Although this approach is still in its
infancy, it suggests the exciting possibility that the ﬁbroblast
rich post-infarct scar could be transformed into functional
myocardium via reprogramming.
A more realistic short-term goal may be to exploit paracrine
signalling to amplify the existent endogenous regenerative
response. Recent cell transplantation experiments conducted in
our laboratory, using an inducible cre-based genetic lineage
mapping approach, tested the hypothesis that cell-based
therapies might exert proregenerative effects via a paracrine
mechanism (Loffredo et al, 2011) (Fig 5). Consistent with some
prior studies (Balsam et al, 2004; Murry et al, 2004), we found
no evidence for transdifferentiation of exogenously delivered
bone marrow cells into cardiac myocytes. However, we did ﬁnd
increased generation of cardiac myocytes from endogenous
progenitors in mice, which were administered c-kitþ bone
marrow cells but not mesenchymal stem cells. This ﬁnding
suggests paracrine signalling between exogenously delivered
cells and endogenous resident progenitors. It provides a
rationale for therapeutic interventions aimed at activating
progenitors or recruiting them from their niche to the injury
site (Steinhauser & Lee, 2009). One such approach involves the
administration of the peptide thymosin b4, which appears to
induce WT-1-expressing epicardial cells to differentiate into
de novo cardiac myocytes (Smart et al, 2011). Interestingly, the
WT-1þcells donot appear todifferentiate into cardiacmyocytes
in theadult mousewithout being primed by thymosin b4,which
suggests the involvement of a reprogramming mechanism.
An alternative to myocyte generation by pharmacologic
means involves stimulating cell-cycle reentry of preexisting
cardiac myocytes. Inhibition of p38 MAP kinase increases
mitotic activity in cardiac myocytes (Engel et al, 2005), although
concomitant growth factor therapy (FGF1) was necessary to
achieve a noticeable improvement in cardiac function (Engel et
al, 2006). The administration of the growth factor neuregulin-1
stimulates mature cardiac myocyte division in vitro, which
translated into a modest increase in the division of the
mononucleated cardiac myocytes in vivo after systemic delivery
of neuregulin (Bersell et al, 2009). Similar stimulation of cardiac
myocyte mitosis was observed after prolonged local delivery of
periostin (Kuhn et al, 2007), an extracellular matrix signalling
protein; however, the effect was not replicated in a transgenic
model of periostin overexpression (Lorts et al, 2009).
Although the regenerative cardiology ﬁeld has primarily
focused on progenitor cells, these data suggest that controlling
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provide an alternative approach to replenishing cardiac
myocytes. A major concern with systemic growth factor
therapy, however, is the potential for mitogenic effects that
may impact other organs. Thus, the future of pharmacologic
regeneration may lie in the local delivery of engineered proteins
and small molecules that target speciﬁc survival, growth and
differentiation pathways.
Future directions
In this review, we have described the current status of
research on cardiac regeneration, highlighting important
recent discoveries and ongoing controversies. The initial
hope that a cell progenitor would emerge with the capacity
to regenerate the injured mammalian heart in the same
manner that bone marrow may be reconstituted has not
been realized in animal studies or randomized clinical
studies. Even if some studies have questioned the
regenerative potency of various endogenous progenitor
populations, it is clearly feasible to reprogramme many cell
types to differentiate into cardiomyocytes. Interestingly,
evolving notions of cellular plasticity may ultimately help to
explain the frustration that many in the ﬁeld have experienced
when attempting to replicate the ﬁndings of landmark studies or
when trying to demonstrate progenitor activity in vivo. It may
well turn out that ex vivo progenitor cultures undergo epigenetic
changes that affect cell fate, and that such modiﬁcations could
account for some of the stem-like properties attributed to
endogenous progenitors.
There is reason for optimism for a regenerative medicine
approach to heart failure, given the intense research
efforts and the capacity of higher organisms, including
the neonatal mouse, to regenerate myocardium. Perhaps
the most important issue in this ﬁeld is identifying which
ﬁndings are consistently supported by multiple experimental
approaches. Ultimately, the ﬁndings that are easily repro-
duced by most or all laboratories will most likely beneﬁt
patients.
The authors declare that they have no conﬂict of interest.
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Pending issues
Dissect the mechanistic differences between adult mammals with
limited regenerative capacity and organisms, such as neonatal mice,
zebrafish and newts, that demonstrate unambiguous cardiac
myocyte regeneration. Understanding these differences may reveal
new pathways that can be therapeutically targeted to achieve more
robust regeneration.
Complete molecular and functional characterization of endogenous
cardiac myocyte progenitors. Multiple laboratories have isolated
progenitors from the heart with different molecular characteristics.
What are the in vivo functional roles of these progenitors? Do the
observed molecular differences between these isolated cells
represent functionally distinct cell types?
Identify paracrine signalling pathways responsible for activation and
recruitment of endogenous cardiac myocyte progenitors. This may
facilitate a pharmacoregenerative therapy, in which treatment with
a protein or small molecule would hold the promise of amplifying
endogenous regeneration.
Refine reprogramming strategies to more efficiently produce mature
cardiac myocytes, both in vitro and in vivo. The ultimate
bioengineering goal is to produce a pure population of mature, fully
functional cardiac myocytes for ex vivo tissue engineering (or) to
control the proliferation and differentiation of endogenous cell
populations or exogenously delivered cell therapies such that scar
tissue is replaced by myocardium. These different strategies are
unified by an underlying requirement to understand the funda-
mental pathways involved in cardiac myocyte differentiation and
maturation.
Immunomodulation
Angiogenesis
Cardioprotection
Exogenous
stem cell
therapy
Endogenous
progenitors
Paracrine
factors
Differentiation
Differentiation
Smooth muscle
cells
Endothelial
cells
Cardiac myocytes
Figure 5. Proposed mechanisms of action for cell-based therapies. In theory, exogenously delivered cells may directly differentiate into endothelial cells,
smooth muscle cells and cardiac myocytes. They may also release paracrine factors which may result in non-regenerative effects, such as immunomodulation,
angiogenesis or cardioprotection. Recent work from our laboratory suggests that a dominant mechanism achieved with bone marrow progenitor therapy may be
via the activation of endogenous progenitor recruitment (Loffredo et al, 2011).
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